多西紫杉醇联合顺铂、5-氟尿嘧啶治疗晚期胃癌的临床研究

Clinical study on docetaxel combining cisplatin and 5-fluorouracil treating advanced gastric cancer

目的：评价多西紫杉醇联合顺铂、5-氟尿嘧啶（DCF）治疗晚期胃癌的临床疗效和毒性反应。方法：用DCF方案治疗晚期胃癌患者28例。结果：可评价疗效者26例，完全缓解（CR）1例，占3．8％；部分缓解（PR）13例，占50．O％；稳定（SD）9例，占34．6％；进展（PD）3例，占11．5％。总有效率（CR＋PR）为53．8％。中位肿瘤进展期5．5个月，中位生存期9．6个月。主要不良反应为白细胞减少23例（88．5％），药物毒性反应Ⅲ～Ⅳ度18例（69．2％），脱发23例（88．5％），腹泻7例（26．9％），口腔炎11例（42．3％），1例发生治疗相关性死亡。结论：多西紫杉醇联合顺铂、5．氟尿嘧啶治疗晚期胃癌临床缓解率较高，提高生存质量，毒副反应可耐受，可以作为难治或复发的晚期胃癌二线治疗方案。

Objective： To evaluate the efficacy and toxicity of DCF regimen （docetaxel plus cisplatin plus 5-fluorouracil） chemotherapy in the treatment of advanced gastric cancer （AGC）. Methods： Twentyeight patients with AGC treated with DCF regimen. Results. Twenty-six patients were evaluated with clinical response, including CR 1 （3.8%）, PR 13 （50.0%）, SD 9 （34.6%）, PD 3 （ 11.5% ）. The total response rate was 53.8%. Median time to progression （mTIP） was 5.5 months and median overall survival time was 9.6 months. The main side effects were： suppression of bone marrow in 23 patients （88.5%）, Ⅲ-Ⅳ 18 （69.2%）, alopecia in 23 （88.5%）, diarrhea in 7 （26.9%） and stomatitis in 11 （42.3%）. There was one death during the treatment. Conclusion： DCF regimen chemotherapy was an effective and well tolerated regimen in the treatment of AGC, which can relieve suffering and improve quality of life of the patients. It can be used as the second-line therapy for relapsed advanced gastric cancer.